The incorporation of anti-IFN-α AAb screening, particularly functional neutralization assays, into early diagnostic algorithms for COVID-19 may enable clinicians to anticipate disease trajectories, escalate monitoring, and guide the early use of immunomodulators. The gene discussed is IFNA1; the disease is COVID-19.